THERAPIX BIOSCI/S (NASDAQ:TRPX) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $8.50 and last traded at $8.64, with a volume of 9915 shares trading hands. The stock had previously closed at $6.70.
Separately, ValuEngine upgraded THERAPIX BIOSCI/S from a “hold” rating to a “buy” rating in a research report on Wednesday, October 31st.
The stock has a market cap of $23.43 million, a PE ratio of 4.30 and a beta of -1.90.
THERAPIX BIOSCI/S (NASDAQ:TRPX) last issued its quarterly earnings data on Monday, August 20th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.24.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/05/therapix-biosci-s-trpx-sets-new-12-month-high-at-8-50.html.
THERAPIX BIOSCI/S Company Profile (NASDAQ:TRPX)
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Read More: Earnings Per Share (EPS) Explained
Receive News & Ratings for THERAPIX BIOSCI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THERAPIX BIOSCI/S and related companies with MarketBeat.com's FREE daily email newsletter.